Moderna stock crashes as leaked melanoma data threatens its record August rally
Moderna's (MRNA) stock dropped sharply after leaked data from a melanoma vaccine trial showed a 42% reduction in cancer recurrence or death, lower than an earlier trial. The stock is on track for its biggest drop on record, erasing over $23 billion in market value. Merck (MRK), Moderna's partner, confirmed the early release of the data. The full results are set for release on Saturday. Moderna's stock had nearly quadrupled since mid-August.
How this was made
The 30-second read
Why it matters
The immediate market reaction is a sharp sell‑off in Moderna, with secondary effects on partner Merck and a brief dip in other biotech names.
Market read
Moderna's stock faces a potential record decline; traders should watch support levels and upcoming conference data.
What to watch
Merck's larger pipeline and diversified revenue may cushion any fallout from this single trial.
Background
Moderna's melanoma vaccine had driven a historic rally in August after early trial success. Leaked data now temper expectations ahead of the official conference presentation.
Ticker impact
Leaked late‑stage melanoma vaccine data caused a sharp sell‑off, pushing Moderna toward its biggest drop on record.
likely pressure as investors reassess the trial's upside and the recent rally
The leak is new information, the stock is already down >20% and a break below key support levels would trigger further selling.
Merck, partner on the melanoma vaccine, fell nearly 4% after the leak but recovered most of the loss.
minor pressure as the vaccine is a smaller component of Merck's business
The drop was brief and Merck's core products dominate its earnings; the leak only marginally affects its share price.
Market effects
Biotech sector may see heightened volatility as other trial data become focal points.
U.S. biotech stocks could face broader sell‑offs in early trading.
Limited to biotech investors; broader indices unlikely to be materially affected.
Counterpoint
The leak may be incomplete; the vaccine's 42% risk reduction could still support a rebound if full data confirm efficacy.
Key entities
- companyModerna
Biotech firm developing personalized melanoma vaccine.
- companyMerck
Partner on the melanoma vaccine, maker of Keytruda.
